| Dermatitis |
0 |
0.9 |
| Pruritus |
0 |
0.99 |
| Biologic Therapy |
0 |
0.65 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.8 |
| Atopic Dermatitis |
0 |
1 |
| Brachial |
0 |
0.25 |
| Translational Research |
0 |
0.25 |
| Acne |
0 |
0.23 |
| Topical Corticosteroid |
0 |
0.22 |
| Corticosteroids |
0 |
0.19 |
| Europe |
0 |
0.13 |
| Monoclonal Antibody |
0 |
0.13 |
| Cornea and External Disease |
0 |
0.09 |
| COVID-19 |
0 |
0.09 |
| Headache |
0 |
0.09 |
| Skin and Soft Tissue Infection |
0 |
0.09 |
| Conjunctivitis |
0 |
0.06 |
| Eczema |
0 |
0.06 |
| Food and Drug Administration (FDA) |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Nausea |
0 |
0.06 |
| Severity Index |
0 |
0.06 |
| Topical Therapy |
0 |
0.06 |
| UK Site Content |
0 |
0.06 |